Disclosed here is a process for the preparation of nitropyridine derivatives of Formula I and its salt and precursors such as halogenated amino pyridines; Formula-I Wherein; R1 is selected from amino group, hydroxyl group, acyl group, alkyl amino group, halogen atom, -NH-C(O)-R3; Where R3 is branched or linear...

A Process for the Preparation of Pharmaceutical Composition of Apixaban. The present invention relates to a process for the preparation of pharmaceutical composition comprising Apixaban, the pharmaceutical composition resulting from this process and its use for the prophylaxis and/or treatment of a thromboembolic di...

The present invention relates to a novel organogel composition for Orobuccal drug delivery. The present invention is directed to provide an organogel system suitable for orobuccal drug delivery using cellulose which readily gels in organic solvent.

N/A

The present invention discloses an improved process for the preparation of moxifloxacin hydrochloride of formula I.

Disclosed  herein  is  an  improved  process  for  the  preparation  of  7-[(3R)-3-aminohexahydro-1H-azepin-1 -yl]-8-chloro-1 -cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid of formula -1 and its pharmaceutically acceptable salt.

The present invention discloses one pot process for the preparation of intermediate 1-C-alkyl hexopyranose compound of Formula I useful in the preparation of Valienamine, Valiolamine and their N-substituted derivative. Formula I wherein R is halo group selected from chlorine, bromine & iodine; and R1 is hydroxyl...

Disclosed herein is a process for the preparation of (R)-N-propargyl-l-aminoindane of Formula - I and its pharmaceutically acceptable salt; .comprising a step of reacting (R) -1 -aminoindane of Formula - II with propargyl derivative of Formula - III wherein x = CI, Br and - ORj; and Rj = mesyl, tosyl, p - methox...

The preseht ihvehtioh discloses a hovel process for the preparatioh of heostigmihe methylsulfate reactihg the compouhd 3—(dimethylamiho)phehol with _dimethylcarbamic halide ih presehce of base, phase trahsfer catalyst ahd solveht to obtaih ah ihtermediate compouhd 3-(dimethylamih6)phehyl dimethylcarbamate. The i...

The present invention provides a low volume, high dose injectable preparation of Diclofenac and/or its pharmaceutically acceptable salts, Macrogol 15 Hydroxystearate as a solubilizer, including other pharmaceutically acceptable excipients with water as a principal solvent and a method of preparing the same. ...

The present invention relates to a Coated Olanzapine Formulation. The present invention relates to a stable formulation of Olanzapine tablets coated with Pullulan gum, starch based coating systems, vinylpyrrolidone-vinyl acetate copolymers or combinations thereof to overcome problem of degradation and discoloration....

The present invention discloses novel process for the preparation of (2R)-2-acetamido-N-benzyl-3-methoxypropanamide of Formula I involving novel intermediates of Formula -XIX and Formula-XX.

Disclosed herein a process for the preparation of compound 4-amino-1-isobutyI-lH-imidazo[4,5-c] quinoline [Imiquimod] of Formula I;

Disclosed herein is a process for preparation of 2-(3-cyaflo-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid of Formula-I comprising Oalkylating the compound ethyl 2-(3-cyano-4-hydroxyphenyI)-4-methyl-thiazole-5-carboxylate of Formula-IX with 2-methyl halo propane of Formula-X followed by hydrolyzing the inter...

The present invention relates to a novel pharmaceutical composition of Linezolid. The present invention relates to a novel pharmaceutical composition comprising linezolid Form III along with pharmaceutically acceptable excipients and a process to prepare the said composition. The present invention relates to an oral...

Disclosed herein is an improved process for the preparation of 3-[(2R,3R)-l-(dimethylamino)-2-methylpentan-3-yl] phenol of Formula - I and its pharmaceutically acceptable salt which comprises the reaction of (S)-l-(dimethylamino)-2-methyIpentan-3-one of formula VIII with 3 - bromo anisole of formula II under Grignar...

The present invention relates to a stable aqueous suspension of Loteprednol etabonate. The present invention relates to an aqueous suspension of Loteprednol etabonate using acetate buffer system. The present invention relates to a method of preparing a stable aqueous suspension of Loteprednol etabonate. ...

A Stable Pharmaceutical Composition. The present invention relates to a stable pharmaceutical composition comprising Leucine, Pyridoxine (Vitamin B6) or Pyridoxal 5 phosphate and pharmaceutically acceptable excipients. The present invention also relates to a method of administering such composition to enhance weigh...

The  present  invention  discloses  a  process  for  the  preparation  of  1 -["(2,6-difluorophenyl)methyl]-lH-l,2,3-triazole-4-carboxamide of Formula 1, Formula I comprising regioselective cycloaddition of 2,6-difluorobenzyl halide of Formula II, wherein X is chloride, bromide or iodide; Formula I! with a c...

The present invention relates to a process for manufacturing sterile Brinzolamide Ophthalmic Suspension. Specifically, the present invention relates to a process for manufacturing sterile ophthalmic suspension comprising Brinzolamide sterilized by Dry Heat Sterilization and pharmaceutical suspension obtained by usin...

Disclosed herein is a process for the preparation of the compound 3-[(2R,3R)-l-(dimethylamino)-2-methylpentan-3-yl]phenol comprising a) reacting compound (2S,3R)-l-(dimethylamino)-3-(3-methoxyphenyl)-2-methylpentan-3-ol with a mixture of methanesulfonic acid and dimethyl sulfide to get the compound (2R)-3-(3-hydroxy...

An improved process for the preparation of (S)-3,4-dihydro-6- chloro-4-hydroxy-2-(3- methoxypropyl)-4H-thieno[3,2-e]-1,2-thiazine ],I -dioxide of Formula-I is disclosed.

N/A

A sustained release oral dosage form comprising of gliclazide or its pharmaceutically acceptable salts, water swellable polymer, buffering agent and one or more pharmaceutically acceptable excipients without any soluble saccharide, sugar or polyol

Disclosed herein is a novel stable pharmaceutical composition by administering the combination therapy comprising combination of lornoxicam, paracetamol, serratiopeptidase which can be used for the treatment of acute painful and inflammatory conditions associated with musculoskeletal and dental problems in mammals. ...

Disclosed here is a process for preparation of compound 11 - (Z) - [3 - (Dimethylamino) propylidene] -6, 11 - dihydrodibenz [b, e] oxepin -2 - yl - acetic acid (Olopatadine) and its pharmaceutically acceptable salt comprising reacting compound of Formula - XII Formula-XII where R1 & R2 independently represent H, or ...

The invention encompasses stable oral pharmaceutical comprising candesartan cilexetil and a stabilizing agent like polyethylene glycol 100-400 or light liquid paraffin. Particularly, the present invention relates to the stable oral pharmaceutical comprising candesartan cilexetil and polyethylene glycol 100-400 or li...

Disclosed herein is a process for preparation of 11 - (Z) - [(3 -Dimethylamino) propylidene] - 6, 11 – dihydrodibenz [b,e] oxepin - 2 - acetic acid (Olopatadine) and its pharmaceutical acceptable salts; comprising reacting carboxylic acid protected 11 – oxo – 6, 11 – Dihydrodibenz [b,e] oxepin – 2 – acetic acid with...

Disclosed herein is an efficient environment friendly process for racemisation of enantiomerically enriched 3 - carbamoyl methyl - 5 - methylhexanoic acid, an important intermediate used for the preparation of (S) - 3 - (amifiomethyl) - 5 - methylhexanoic acid.

The present invention relates to process for the preparation of ethyl 6 - [2 - (4, 4 -dimethylthiochroman - 6 - yl) ethynyl] nicotinate and its pharmaceutical acceptable salt.

The invention relates to a novel single step process for the preparation of tablet dosage form. In particular, the invention relates to a novel process for the preparation of tablet dosage form which is cost effective, trounces the problems of hydrophobicity of lubricants like magnesium stearate and obviates the nee...

The present invention relates to an improved process for the preparation of N- {2-[4-(aminosulfonyl) phenyl] ethyl} –3ethyl-4-methyl-2oxo-2, 5-dihydro-1H-pyrrole-1-carboxamide. This compound is useful as a key intermediate in the synthetic preparation of trans-3-Ethyl-2, 5-dihydro-4-methyl-N- [2- [4- [[[[(4-methyl c...

Disclosed here is a process for the preparation of 3 - amino pyrazole derivative of Formula -1 Formula -1 Where R1 = H, C1 - C4 alkyl group or benzyl group or phenyl group; R2 = C1 - C6 alkyl group or benzyl group; comprising a step of reacting the compound of Formula - III, with hydrazine hydrate Formula - III....

The present invention describes an improved method for the preparation of l-[4-{2-(cyclopropylmethoxy)ethyl}phenoxy]-3-[(l-methylethyl)amino]-2-propanol of Formula-I and its pharmaceutically acceptable salt, which comprises reacting 4 - [ 2 -(Cyclopropylmethoxy) ethyl] phenol with epichlorohydrin in presence of mild...

The present invention discloses novel pharmaceutical compositions comprising morphine or its analogs, lactulose and other suitable pharmaceutical excipients in effective amounts for reducing the side effects associated with use of morphine and its analogs during cough. The present invention further discloses a metho...

The present invention discloses a novel, stable aqueous pharmaceutical injectable composition of Diclofenac sodium in benzyl alcohol as a lone excipient, which is devoid of side effects. The invention further discloses process for preparation of a stable pharmaceutical composition of diclofenac sodium by a simple, c...

Disclosed herein is a process for the preparation of substituted derivatives of 3 - Benzoyl - 2 - amino phenylacetic acid of Formula - I and its pharmaceutically acceptable salts; which comprises the (i) protection of compound 2 - nitro benzophenone of Formula - XV to get the compound of Formula - XVI;(ii) reaction ...

Disclosed herein is a novel process for the preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and novel intermediates thereof.

The present invention discloses novel pharmaceutical combination compositions comprising ranitidine, lactulose and other suitable pharmaceutical excipients in effective amounts useful for the treatment of constipation as well as acid-related gastrointestinal disorders. The present invention further discloses a metho...

Disclosed herein is stable pharmaceutical composition of olopatadine which comprises, gamma irradiated polyvinyl pyrrolidone and other pharmaceutical ly acceptable excipients. 24 NOV 2008" 14

A pharmaceutical composition providing controlled delivery of methylcobalamin designed to improve the bioavailability of the drug in the upper gastrointestinal tract is described. The pharmaceutical composition is formulated into a tablet dosage form. The pharmaceutical composition comprises of a drug, a gas generat...

Disclosed herein is a process for preparation of endo-(±)-α-hydroxybenzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester [Homatropine] of formula I and its pharmaceutically acceptable salt which comprises reaction of tropine with an ester of phenyl glyoxalic acid to obtain tropine phenyl glyoxalate or its ac...

The invention discloses an efficient process for purification of crude Bosentan of Formula I which selectively removes the bis-sulfonamide (Formula III) impurity to less than 0.05% to undetectable limit and deshydroxyethyl bosentan (Formula IV) impurity to less than 0.1% to obtain substantially pure compound Bosenta...

The present invention discloses novel sustained release dosage forms of quetiapine or its pharmaceutical acceptable salt. Further, the present invention relates to a method for preparing the sustained release pharmaceutical tablet composition which is simple, convenient, and economical to manufacture. ...

The present invention discloses a novel process for the preparation of Dapagliflozin (S)-propylene glycol hydrate of Formula II. Formula II

The present invention relates to a process for the purification of vildagliptin comprising the formation of vildagliptin-saccharin adduct of formula III.

The present invention relates to a process for the preparation of Anagliptin, the compound of formula I and its novel intermediates.

The present invention relates to a novel process for preparation of 7-[(3R)-3-aminohexahydro-1H-azepin-1 -yl] -8-chloro-1 -cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid hydrochloride (besifloxacin hydrochloride) of formula - I using novel intermediate compounds of formula - II...

The present invention relates to a stable ophthalmic gel forming solution comprising Lidocaine & other pharmaceutical excipients. The present invention also relates to an ophthalmic gel forming solution comprising of low concentration of preservative. The gel forming solution on contact with tear fluid transforms in...

The present invention discloses a novel process for the preparation of alogliptin and its pharmaceutically acceptable salt.

The present invention relates to a Stabilization of Prostaglandins. The present invention relates to method of increasing the stability of pharmaceutical composition comprising prostaglandin and pharmaceutically acceptable excipients wherein the method comprises of providing composition in polyethylene conta...

The present invention relates to a stable gel forming solution. More particularly, the present invention relates to a stable solution comprising Timolol, which forms gel on contact with tear fluid. The invention further relates to process for preparation of stable gel forming solution. The present invention ...

The present invention relates to an improved process for the preparation of dorzolamide hydrochloride the compound of Formula I.

The present invention relates to an improved process for purification of posaconazole of Formula I and a novel polymorph thereof.

The present invention discloses an improved process for the preparation of Brexpiprazole and its pharmaceutically acceptable salt. The present invention further discloses a process for purification of Brexpiprazole to reduce or eliminate all known and unknown impurities.

The present invention relates to an improved process for the preparation of empagliflozin of Formula I and its novel intermediates.

The present invention relates to novel pharmaceutical^ acceptable salts of sitagliptin of Formula I, their polymorphs and process for preparation thereof.

Abstract A Stable Ophthalmic Composition. The present invention relates to a stable ophthalmic composition. Specifically, the present invention relates to a travoprost ophthalmic composition and a method of preparing same, which is chemically stable at room temperature, compatible to the low-density polyethylene (L...

The present invention relates to a stable ophthalmic composition of posaconazole and method of preparing same, which is chemically stable at room temperature. The composition of the present invention is a stable and sterile aqueous ophthalmic composition. Specifically, the present invention relates to an ophthal...

The present invention discloses to a process for the preparation of brexpiprazole and its pharmaceutically acceptable salt. The present invention further discloses novel intermediates and process for the preparation of the novel intermediates of brexpiprazole. The invention also discloses a process for purification...

The present invention relates to a process for the preparation of the compound ethyl trans-2-(4-aminocyclohexyl)acetate and its salt of Formula I;

Abstract A stable spill resistant syrup The present invention relates to a stable spill resistant syrup comprising of combination of acetaminophen, chlorpheniramine maleate, phenylephrine and other pharmaceutical excipients. The present invention also relates to taste masked spill resistant syrup which is stable a...

A Stable Ophthalmic Composition of Miconazole The present invention relates to miconazole ophthalmic composition and a method of preparing same, which is chemically stable at room temperature. The composition of the present invention is stable and sterile aqueous ophthalmic composition. Specifically, the present in...

The present invention discloses a novel process for the preparation of (S)-3-amino-2-(4-methylphenyl)propanoic acid and novel intermediates thereof. The present invention further discloses preparation of novel intermediates during the preparation of (S)-3-amino-2-(4-methylphenyl)propanoic acid. ...

The invention relates to a process for the purification of crude rivaroxaban the compound of formula -I.

40 ABSTRACT 5 ORAL COMPOSITION CONTAINING NARINGIN AND USES THEREOF The present invention relates to an oral composition comprising an effective amount of naringin, Zingiber officinale extract, and one or more other actives along with 10 pharmaceutically acceptable excipients; and a process for its preparation...

A Stable Ophthalmic Nanosuspension of Brinzolamide. The present invention relates to a stable ophthalmic nanosuspension of brinzolamide and a method of preparing same, which is chemically stable at room temperature and free of quaternary ammonium salt. Moreover, the composition of present invention is sterile aqueo...

The present invention relates to a process for preparation of succinylcholine chloride dihydrate of formula 1.

The present invention relates to a process for the preparation of sitagliptin hydrochloride and its polymorph sitagliptin hydrochloride monohydrate of Formula la thereof.

The present invention relates to a stable injectable composition of Triamcinolone acetonide and a method of preparing same, which is stable at controlled room temperature between 20°C- 25°C and packaged in glass material. Specifically, the triamcinolone acetonide injection of the present invention shows improved vis...

The present invention covers a stable oral dosage form of Lofexidine with improved content uniformity. The present invention also provides a composition and manufacturing process to prepare a stable Lofexidine dosage form, along with physical properties and stability data for the final product. The present invention...

The present invention relates to novel polymorphic form III of glimepiride of formula I and process for preparing the same.